Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Australian Laboratory Services Pty Ltd, EML Pty Ltd, DFC Pharmamed, C LIM Consulting

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was established to regulate the quality, efficacy, and safety of therapeutic goods available in Australia. The Act addresses the need to ensure that therapeutic goods, including medicines, medical devices, and blood products, meet necessary standards before they are supplied to the public. The Therapeutic Goods Administration, which is part of the Department of Health and Ageing, administers the Act with the overarching policy objective of protecting public health by ensuring that therapeutic goods are of acceptable quality and are safe for use. The 2013 Gazette, published under section 41 of the Act, notifies the revocation of manufacturing licenses for certain therapeutic goods at the request of the manufacturers themselves, highlighting the regulatory framework's flexibility in addressing compliance and operational changes within the industry.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration, governs the regulation of therapeutic goods in Australia. The Act applies to a broad range of entities, including individuals and companies, involved in the manufacture, supply, and importation of therapeutic goods. It encompasses the entire national territory, thus extending its reach across the Commonwealth, states, and territories of Australia. The Act provides for the licensing of manufacturers and suppliers of therapeutic goods, and the revocation of such licenses under specific circumstances, as illustrated by the revocation of licenses for several entities detailed in the notice. The Act’s application can be further extended or refined through subordinate instruments, which may specify additional requirements or clarifications for compliance. The notice in question, signed by the Delegate of the Secretary, specifies the revocation of manufacturing licenses for various entities at their own request, indicating that the Act allows for voluntary relinquishment of such licenses under certain conditions.

Key Provisions

The main operative section of the Therapeutic Goods Act 1989 in this Gazette, section 41(1)(d), allows the Secretary to revoke licences for the manufacture of therapeutic goods. Specifically, the Secretary has the authority to issue a written notice revoking such licences at the request of the manufacturer. In this instance, the Secretary has exercised this power by revoking the licences held by several entities, including Australian Laboratory Services Pty Ltd, EML Pty Ltd, DFC PharmaMed, and C Lim Consulting. These revocations were carried out at the request of the respective manufacturers, as stipulated in the notice. The Act imposes certain obligations on the parties involved in the manufacture of therapeutic goods. The manufacturers who hold these licences are required to comply with the conditions of their licences, which may include requirements for quality control, record-keeping, and adherence to specific manufacturing standards. When a manufacturer requests the revocation of their licence, it indicates their intention to cease operations or their compliance with the Act’s stipulations in a manner that makes continued licensing unnecessary. The Secretary, through the Therapeutic Goods Administration, reviews these requests and, if satisfied, proceeds with the revocation as outlined in the Gazette. The Therapeutic Goods Act 1989 does not explicitly state offences, penalties, or consequences for the revocation of manufacturing licences. However, the process of revocation itself can be seen as a regulatory measure to ensure compliance with the Act. If a manufacturer continues to operate without a valid licence, they could face potential offences under other sections of the Act, such as manufacturing therapeutic goods without a licence, which could result in civil or criminal penalties. For example, under section 22 of the Act, a person who contravenes a prohibition against manufacturing therapeutic goods without a licence can be fined up to 500 penalty units or imprisoned for up to two years, or both. These penalties underscore the importance of adhering to the regulatory framework set by the Act.